|
Corporate Profile
Lexicon Pharmaceuticals is a biopharmaceutical company focused on drug discovery and development. Our company is dedicated to discovering and developing breakthrough treatment for human disease based on understanding how genes function.
We have used our proprietary gene knockout technology on an unprecedented scale to systematically discover the physiological and behavioral functions of almost 5,000 genes. Through this initiative, known as the Genome5000™ program, we have identified and validated more than 100 drug targets and created a unique, growing clinical pipeline.
All of our drug targets have been identified internally as part of our Genome5000 program. Currently, we are working towards commercialization of our discoveries in order to fight human diseases in cardiology, gastroenterology, immunology, metabolism, and ophthalmology. Our goal is to enhance the lives of patients by discovering and developing breakthrough treatments for human disease.
Investor Highlights
- Multiple drug candidates in human clinical trials identified through our Genome5000 program
- LX1031 in Phase 2 clinical trials for irritable bowel syndrome
- LX1032 in Phase 2 clinical trials for symptoms associated with carcinoid syndrome (Fast Track status in U.S.; Orphan designation in EU)
- LX2931 in Phase 2 clinical trials for rheumatoid arthritis
- LX4211 in Phase 2 clinical trials for diabetes
- Alliances with large pharmaceutical and biotechnology companies
- A $60 million clinical development collaboration with an investor group led by Symphony Capital Partners, L.P.
- A $550 million investment plan (see below)
Lexicon's Five-Year Investment Plan
In June 2007, Lexicon entered into a major financing agreement with Invus, L.P. (“Invus”) to help fund its strategic goal of transitioning into an integrated biopharmaceutical company. Under the agreement, Invus invested $205 million in 2007. In addition, Lexicon stockholders, including Invus, may invest an additional $345 million over the next several years. These investments may provide up to approximately $550 million in operating capital to help Lexicon achieve its drug development objectives.
 Corporate Profile/Fact Sheet
Investor and Media Relations Contact
D. Wade Walke, Ph.D.
Senior Director, Corporate Communications
Lexicon Pharmaceuticals, Inc.
8800 Technology Forest Place
The Woodlands, TX 77381-1160
281.863.3000
Corporate Affairs Contact
Steven Tragash
Senior Vice President, Corporate Affairs
Lexicon Pharmaceuticals, Inc.
8800 Technology Forest Place
The Woodlands, TX 77381-1160
281.863.3000
|
